Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/m...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivot, Xavier, Im, Seock Ah, Guo, Matthew, Marmé, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906517/
https://www.ncbi.nlm.nih.gov/pubmed/29302858
http://dx.doi.org/10.1007/s12282-017-0826-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906517/
https://www.ncbi.nlm.nih.gov/pubmed/29302858
http://dx.doi.org/10.1007/s12282-017-0826-4

Ejemplares similares